This content is for informational and research purposes only. Not medical advice. Consult a licensed physician before starting any hormone or peptide therapy.
There is a specific and recurring absurdity in the peptide research world: compounds that have been in regular use by athletes, bodybuilders, and performance-minded individuals for over twenty years continue to be written up in peer-reviewed journals as though they are novel discoveries. The people in the gym already know about it. The researchers are just now publishing papers about it like it's news from 1987.
The ipamorelin CJC-1295 protocol — the most popular growth hormone secretagogue stack in research and performance circles — is a perfect example of this phenomenon. The stack has been discussed in online forums with near-encyclopedia depth since at least 2008. Meanwhile, academic publications continue to arrive with titles like "Novel GHRP Receptor Agonists: A Preliminary Investigation," which is the scientific equivalent of discovering fire and calling it a promising new heating method.
This guide explains what ipamorelin and CJC-1295 are, why the stack works the way it does, the research-backed dosing and timing protocols, and how to track a GH peptide protocol in a way that produces useful data rather than a vague sense that something might be happening to your sleep quality.
What Are Growth Hormone Secretagogues?
A growth hormone secretagogue (GHS) is a compound that stimulates the pituitary gland to release growth hormone — as opposed to exogenous HGH, which is simply injecting the hormone directly. The distinction matters more than it might initially appear.
Exogenous HGH produces a continuous elevation of growth hormone in the bloodstream. It's effective, but it suppresses the pituitary's natural GH production over time and produces supra-normal, non-pulsatile GH levels. It is also expensive, tightly regulated, and carries side effects related to persistent GH elevation (acromegaly risk, carpal tunnel syndrome, and others with chronic high-dose use).
Growth hormone secretagogues work differently. They stimulate the pituitary to produce a pulse of GH — the way the body naturally releases it. GH in the healthy body is released in pulses, predominantly during deep sleep, with smaller pulses at other times. Secretagogues amplify or trigger these pulses rather than replacing the pituitary's function. This means the body retains its feedback mechanisms — the hypothalamic-pituitary axis continues to function, natural production is preserved during cycle, and the GH profile remains pulsatile rather than flat. The safety profile is consequently more favorable than exogenous HGH for most research applications.
There are two classes of secretagogue relevant to the ipamorelin/CJC-1295 stack:
- GHRPs (Growth Hormone Releasing Peptides) — mimic ghrelin and stimulate GH release directly from the pituitary via the ghrelin receptor. Ipamorelin is in this class.
- GHRHs (Growth Hormone Releasing Hormones) — act on the hypothalamus to amplify the GH pulse triggered by GHRPs. CJC-1295 is in this class.
Using one from each class simultaneously is the principle behind the stack. They hit different receptors, via different mechanisms, and the result is a GH pulse larger than either would produce alone.
Ipamorelin Explained — The Selective GH Pulse
Ipamorelin is a pentapeptide — five amino acids — that acts as a selective agonist at the ghrelin receptor (GHS-R1a) in the pituitary gland. When it binds, it triggers a pulse of growth hormone release. The word "selective" in its description is doing significant work and should not be glossed over.
Earlier GHRPs — specifically GHRP-2 and GHRP-6 — also triggered GH release, but they came with a cost: both compounds produced measurable increases in cortisol and prolactin alongside GH. Elevated cortisol is directly catabolic (counterproductive for someone using the peptide to support body composition) and elevated prolactin causes its own set of unpleasant side effects. GHRP-6 additionally produced significant increases in hunger, mediated by ghrelin receptor activity in the gut — which is useful if you're trying to eat more, and inconvenient if you're not.
Ipamorelin does not meaningfully raise cortisol. It does not raise prolactin. It does not substantially increase hunger. It produces a clean, selective GH pulse. This is why it became the dominant GHRP in research use: the specificity makes it more practical for actual sustained protocols rather than occasional use where side effects are less consequential.
Research ipamorelin dosing is typically in the range of 200–300mcg per injection. The half-life is approximately 2 hours, which means it produces a short, sharp pulse rather than a sustained elevation. This pharmacokinetic property makes timing important — you want to inject when GH release will be most beneficial, not when insulin levels will blunt the response.
CJC-1295 Without DAC — The GHRH Amplifier
CJC-1295 is a modified GHRH analog — a synthetic version of the body's own growth hormone releasing hormone, with modifications that improve its stability and extend its effective half-life beyond the ~7 minutes of native GHRH. It works at the hypothalamus, amplifying the GH pulse that ipamorelin triggers at the pituitary. The two mechanisms are complementary at the physiological level.
The "without DAC" specification is important. CJC-1295 comes in two forms: with Drug Affinity Complex (DAC) and without. CJC-1295 with DAC has an extended half-life of approximately 8 days, producing a sustained, non-pulsatile elevation of GHRH signaling — which effectively produces constant GH stimulation rather than pulsatile release. This blunts the natural pulsatile pattern that preserves receptor sensitivity and feedback control. CJC-1295 without DAC (sometimes called "Modified GRF 1-29" or "Mod GRF") has a half-life of approximately 30 minutes, which produces a pulse synchronized with the ipamorelin injection rather than a chronic background elevation.
For most research protocols, CJC-1295 without DAC is preferred specifically because it maintains the pulsatile GH release pattern. Constant GH elevation leads to GH receptor desensitization over time, which is the opposite of what a sustainable protocol aims for.
Research dosing for CJC-1295 without DAC: 100–200mcg per injection, combined with ipamorelin in the same syringe. The two peptides are compatible in solution and are routinely co-administered in a single subcutaneous injection.
The Ipamorelin + CJC-1295 Stack Protocol
The rationale for the ipamorelin CJC-1295 stack is synergistic: ipamorelin (GHRP) triggers GH release at the pituitary; CJC-1295 without DAC (GHRH) amplifies the hypothalamic signal that enhances that pulse. Together, they produce a GH release significantly larger than either would alone — research suggests the combination amplifies the pulse by approximately two to three times compared to either peptide in isolation.
The protocol that has emerged from research use:
- Ipamorelin: 200–300mcg per injection
- CJC-1295 without DAC: 100–200mcg per injection, combined in the same syringe
- Timing: Pre-sleep is the most common and generally preferred window. The body's largest natural GH pulse occurs in deep sleep; injecting 30–60 minutes before bed amplifies this pulse rather than creating an artificial one at an arbitrary time. Fasted AM (before eating, before training) is the second most common option. Critically: not after meals. Elevated insulin from carbohydrate ingestion blunts GH release — this is a well-established physiological antagonism. Injecting post-meal reduces effectiveness substantially.
- Frequency: Once daily (pre-sleep only) is the most common protocol. Twice daily (fasted AM + pre-sleep) is used in some protocols for more aggressive GH optimization. There is diminishing return past twice daily due to receptor saturation and feedback dynamics.
- Cycle length: 8–12 weeks, followed by a 4-week break. The off-cycle period is important for maintaining receptor sensitivity and preserving the natural GH pulse pattern. Using secretagogues continuously without breaks may lead to pituitary desensitization over time.
Insulin blunts GH release. Injecting after a large carbohydrate meal is the most reliable way to pay for peptides and get a fraction of their effect.
Tracking Your GH Stack — What to Log and Why
GH peptide tracking requires a different mindset than, say, TRT tracking, because you cannot easily get a blood test that directly reflects your GH pulse amplitude at a reasonable cost or frequency. IGF-1 is the most practical proxy — serum IGF-1 reflects cumulative GH secretion and is a reasonable marker of whether your stack is producing GH stimulation — but even IGF-1 testing every few weeks is more commitment than most people make. So what do you actually log, and why does it matter?
The most practically useful markers to track on an ipamorelin CJC-1295 protocol:
- Sleep quality — this is the most sensitive and most accessible proxy. GH-dependent deep sleep (slow-wave sleep) tends to improve noticeably within the first 1–2 weeks of a functioning GH secretagogue protocol. If you're not sleeping better on a pre-sleep ipamorelin/CJC protocol after two weeks, either the timing or the product quality warrants investigation. Log a 1–5 sleep quality rating each morning. The trend over weeks is more informative than any individual score.
- Body composition trends — GH has lipolytic effects (mobilizes fat) and supports lean tissue preservation and growth, but these changes are gradual. Weeks, not days. Log body weight weekly, waist measurement monthly, and progress photos at the start and end of each cycle. The visual comparison at cycle end versus cycle start — not the day-to-day scale weight — is where the signal lives.
- Dose and timing compliance — specifically the fasted window. If you inject at midnight on weekdays and after dinner on weekends because the weekend schedule is different, you've introduced a variable that will muddy your self-assessment. Log actual injection times, not intended ones. If you find the pre-sleep dose is often falling outside the fasted window, adjusting the timing is more useful than adjusting the dose.
- Cycle start and end dates — obvious but frequently neglected. When you return to a stack after the off-cycle break, knowing that the previous cycle was 10 weeks and produced specific outcomes allows you to make a more informed decision about whether to lengthen or shorten the next one. Memory is not a reliable protocol management tool across a 12-week window.
The GH peptide tracker function of a proper protocol log is not glamorous. It is: did I inject within the fasted window tonight, did my sleep score go up this week, is my waist measurement still tracking in the right direction at week eight. Tedious to describe. Genuinely useful in practice, especially if you run multiple compounds and need to attribute improvements to specific interventions.
If you're running ipamorelin/CJC alongside a TRT protocol, logging both in the same place and correlating outcomes across compounds is where the data becomes valuable. You can track your TRT serum levels and body composition alongside GH peptide cycles and start to understand your individual response with some precision. ZAP handles both the TRT tracking and the peptide cycle logging in one place, which is more useful than it sounds when you're 10 weeks into a stack and can't remember exactly when you started.